Tag: information

SINGAPORE, June 10, 2026 /PRNewswire/ -- Motul is proud to be the official lubricant partner of Great Wall Motor (GWM) Factory Racing for the...

A new cellulose-based material platform developed in Finland responds to tightening regulatory requirements and industry pressure to both replace and reduce plastic in packaging,...

New TVC on ARD and ZDF delivers how quiet discipline drives both elite sport and autonomous lawn care.DÜSSELDORF, Germany, June 10, 2026 /PRNewswire/ --...

STOCKHOLM, June 10, 2026 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-powered skin health solutions, today announced that the first...

New body of vibrant, expressive paintings explores consciousness, intuition, and the power of feeling — featuring powerful works incorporating Bruce Lee's iconic philosophy; artist...

Vara receives EU MDR CE mark for its tomosynthesis (3D mammography) AI, extending Europe's leading screening-grade AI portfolio to 3D imaging.

Synack and Wolfpack Information Risk Bring Sara AI Pentesting to Organizations Across South Africa

Edmonton-born PropTech company draws property managers, investors, real estate operators, technology leaders, government representatives, academia, community leaders, and media to unveil the future of AI-assisted property operations

Edmonton-born PropTech company draws property managers, investors, real estate operators, technology leaders, government representatives, academia, community leaders, and media to unveil the future of AI-assisted property operations

Worldwide launch of EARTH DEFENSE FORCE 5 scheduled for October 8, 2026; EARTH DEFENSE FORCE 6 planned for release this winterTOKYO, June 10, 2026...

AUSTIN, Texas and DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced the pricing of its previously announced a public offering of 10,879,376 shares of its common stock at a public offering price per share of $4.00 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 7,870,624 shares of its common stock at a public offering price of $3.9999 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.0001 per share and are exercisable immediately. The aggregate gross proceeds to Shattuck from the offering are expected to be approximately $75 million before deducting underwriting discounts and commissions and other offering expenses payable by Shattuck, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on June 11, 2026, subject to the satisfaction of customary closing conditions. In addition, Shattuck has granted the underwriters an option for a period of 30 days to purchase up to an additional 2,812,500 shares of its common stock at the public offering price, less underwriting discounts and commissions.